Home > News > Acromegaly in Pregnancy—An Overview of the Key Issues
Pituitary Disorders
Read Time: 2 mins

Acromegaly in Pregnancy—An Overview of the Key Issues

Published Online: May 14th 2012 US Endocrinology, 2012;8(1):53-6 DOI: http://doi.org/10.17925/USE.2012.08.01.53
Authors: Trina McIlhargey, Bernard Corenblum
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Acromegaly in pregnancy is a rare occurrence and the literature regarding its diagnosis and management is limited. Normal pregnancies have a physiologic increase in growth hormone due to the production of a variant form by the placenta. Conventional assays are unable to differentiate pituitary from placental growth hormone and, as a result, making a diagnosis of acromegaly or assessing biochemical control in pregnancy is a challenge. While risks to the patient and fetus exist, they are mainly limited to complications associated with insulin resistance—which, if present, should be monitored and treated. Tumor enlargement may occur if therapy is discontinued at the start of pregnancy, but this is usually not the case and most have an uneventful pregnancy. Consequently, definitive diagnosis or treatment can often be delayed until after delivery—although, when indicated, treatment with dopamine agonists or somatostatin analogs is a reasonable option. To date, there are no data to suggest adverse outcomes with these agents; however, limited evidence is available and they should only be used in severely symptomatic acromegalics or those with symptomatic tumor enlargement. Transsphenoidal surgery is associated with an increased rate of pre-term labor and fetal loss, and should be considered only in emergency situations such as pituitary apoplexy.

Keywords

Acromegaly, pregnancy, diagnosis, management

Article:

Acromegaly in pregnant women is an uncommon clinical problem. However, today, due to earlier diagnosis, women present with this concern at a younger age. In patients with pre-existing acromegaly, there may be difficulty conceiving, there are concerns regarding maternal and fetal outcomes, and there are no good data to fully assess the risk:benefit ratio of the various therapies that could be used during pregnancy. Acromegaly diagnosed for the first time during pregnancy is another clinical problem.

Acromegaly in pregnant women is an uncommon clinical problem. However, today, due to earlier diagnosis, women present with this concern at a younger age. In patients with pre-existing acromegaly, there may be difficulty conceiving, there are concerns regarding maternal and fetal outcomes, and there are no good data to fully assess the risk:benefit ratio of the various therapies that could be used during pregnancy. Acromegaly diagnosed for the first time during pregnancy is another clinical problem.

Acromegaly is a rare disease with an annual incidence of three to four per million people,1 characterized by excessive production of growth hormone (GH) from somatotroph cells in the pituitary gland, almost always from an adenoma. Acromegaly in pregnancy is even more rare and limited data are available, mainly as a consequence of the reduced fertility often found in women with pre-existing pituitary disease.

Pituitary Changes in Normal Pregnancy
Magnetic resonance imaging (MRI) scans performed during pregnancy demonstrate a gradual increase in maternal pituitary volume over the course of gestation, with an increased final weight (660–760 mg) as well as a volume increase of 30 % above the pre-gestational volume.2,3 This enlargement results in a homogeneous upward convexity of the superior surface of the gland when visualized radiologically, and the gland reaches 12 mm in height a few days post-partum. It usually does not increase more than 2.6 mm. The pituitary gland increases in all dimensions, with an average increase of 136 %.2

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

The authors have no conflicts of interest to declare.

Correspondence

Bernard Corenblum, MD, FRCPC, Richmond Road Diagnostic and Treatment Center, 1888–1820 Richmond Road, Calgary, Alberta, T2T 5C5, Canada. E: corenblu@ucalgary.ca

Received

2012-06-03T00:00:00

Further Resources

Share this Article
Related Content In Pituitary Disorders
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72